subject.id	manuscript.id	arm	treatment	crossover.to.ipi.nivo	crossover.day	age	sex	race	ethnicity	tumor.type	tumor.type.abbr	prior.lines.of.therapy	ecog.screening	stage.at.diagnosis	stage.at.enrollment	treatment.duration.months	cd8.percent.baseline	cd8.percent.max.ontrt	best.overall.response	pfs.months	pfs.event.flag	os.months	os.event.flag	responder.flag.crpr	disease.control.flag	cd8.converter.flag	msi	tmb	response_label	tumor.type.tcga	$P_{NR}$	$P_{R}$	pred_response
101-0001	1	CD8 LOW	Nivolumab + Ipilimumab			61	F	Other	Not Hispanic or Latino	Pancreatic carcinoma	PANC	3	0.0	Stage 4	Stage 4	1.4127310061601643	6	3.0		4.008213552361396	1	4.008213552361396	1	N	N	N	MSI-L	0.97		PAAD	1.0	8.701194e-14	NR
101-0007	6	CD8 LOW	Nivolumab + Ipilimumab			71	F	Other	Not Hispanic or Latino	Non-small cell lung cancer	LUCA	1		Stage 2	Stage 4	2.9568788501026693	1	30.0	Partial Response	13.864476386036962	1	13.9958932238193	0	Y	Y	Y	MSI-L	0.69	R	LUAD	3.4275315e-06	0.99999654	R
101-0008	7	CD8 LOW	Nivolumab + Ipilimumab			53	F	White	Hispanic or Latino	Ovarian cancer	OVCA	3	1.0	Stage 3	Stage 4	26.87474332648871	11	36.0	Complete Response	11.071868583162216	1	36.63244353182752	0	Y	Y	Y	MSI-Stable	3.5	R	OV	0.92980874	0.07019128	NR
101-0011	9	CD8 LOW	Nivolumab + Ipilimumab			44	F	Other	Not Hispanic or Latino	Breast cancer	BRCA	5+	0.0	Stage 1	Stage 4	2.891170431211499	5	5.0	Progressive Disease	1.9712525667351128	1	3.2525667351129366	0	N	N	N	MSI-Stable	0.45	NR	BRCA	0.9999968	3.256932e-06	NR
101-0017	73	CD8 HIGH	Nivolumab	Y	130.0	63	F	White	Not Hispanic or Latino	Ovarian cancer	OVCA	3	0.0	Stage 3	Stage 4	5.749486652977413	19	25.0	Stable Disease	3.5811088295687887	1	22.143737166324435	1	N	N		MSI-Stable	1.14	NR	OV	0.9999995	4.173116e-07	NR
102-0001	14	CD8 LOW	Nivolumab + Ipilimumab			58	M	White	Not Hispanic or Latino	Head and neck cancer	HNCA	3	1.0	Stage 4	Stage 4	0.7227926078028748	1	6.0	Progressive Disease	1.4127310061601643	1	7.917864476386038	1	N	N	N	MSI-L	1.01	NR	HNSC	0.99999356	6.450648e-06	NR
102-0006	15	CD8 LOW	Nivolumab + Ipilimumab			52	M	Other		Gastric cancer	GSCA	5+	1.0	Stage 2	Stage 4	0.0328542094455852	10			1.2813141683778233	1	1.2813141683778233	1	N	N		MSI-Stable	2.44		STAD	2.0411284e-05	0.9999796	R
102-0011	17	CD8 LOW	Nivolumab + Ipilimumab			40	M	White	Not Hispanic or Latino	Mixed hepatocellular cholangiocarcinoma	HECH	5+	1.0	Stage 4	Stage 4	1.4127310061601643	4	9.0	Progressive Disease	2.0698151950718686	1	2.102669404517454	0	N	N	N	MSI-Stable	0.5	NR	LIHC	0.9758782	0.024121827	NR
102-0013	18	CD8 LOW	Nivolumab + Ipilimumab			72	M	White	Not Hispanic or Latino	Sarcoma	SARC	5+	0.0	Stage 4	Stage 4	9.00205338809035	9	35.0	Stable Disease	3.449691991786448	1	25.100616016427107	1	N	N	Y	MSI-Stable	1.25	NR	SARC	1.0	5.460485e-09	NR
102-0016	20	CD8 LOW	Nivolumab + Ipilimumab			53	M	Black or African American	Not Hispanic or Latino	Sarcoma	SARC	2	1.0	Stage 2	Stage 4	4.402464065708419	1	42.0	Progressive Disease	2.0698151950718686	1	7.62217659137577	1	N	N	Y	MSI-H	1.4	NR	SARC	1.0	1.6450156e-14	NR
102-0018	22	CD8 LOW	Nivolumab + Ipilimumab			48	F	White	Not Hispanic or Latino	Mixed hepatocellular cholangiocarcinoma	HECH	4	1.0	Stage 4	Stage 4	0.0328542094455852	9		Progressive Disease	1.3141683778234086	1	13.963039014373717	1	N	N		MSI-Stable	0.76	NR	LIHC	0.9999784	2.15335e-05	NR
102-0019	23	CD8 LOW	Nivolumab + Ipilimumab			67	M	White	Not Hispanic or Latino	Prostate cancer	CRPC	5+	1.0	Stage 3	Stage 4	1.4127310061601643	5	38.0	Progressive Disease	2.004106776180698	1	5.355236139630391	1	N	N	Y	MSI-Stable	1.02	NR	PRAD	0.00038444693	0.99961555	R
102-0024	26	CD8 LOW	Nivolumab + Ipilimumab			53	M	White	Not Hispanic or Latino	Prostate cancer	CRPC	3	1.0	Stage 2	Stage 4	0.7227926078028748	9		Stable Disease	1.5441478439425054	0	24.04928131416837	0	N	N		MSI-Stable	16.13	NR	PRAD	0.21912494	0.780875	R
102-0025	27	CD8 LOW	Nivolumab + Ipilimumab			63	F	Other	Not Hispanic or Latino	Peritoneal sarcoma	PRTC	5+	1.0	Stage 4	Stage 4	4.139630390143737	0	1.0	Progressive Disease	2.036960985626284	1	28.15605749486653	0	N	N	N	MSI-Stable	0.57	NR	SARC	1.0	2.3177091e-09	NR
102-0029	30	CD8 LOW	Nivolumab + Ipilimumab			59	F	Other	Not Hispanic or Latino	Neuroendocrine carcinoma	NEUC	2	1.0	Stage 4	Stage 4	9.659137577002054	0	2.0	Partial Response	13.897330595482549	1	13.897330595482549	1	Y	Y	N	MSI-L	16.05	R	OTHER	4.991491e-05	0.99995005	R
102-0030	31	CD8 LOW	Nivolumab + Ipilimumab			76	M	White	Not Hispanic or Latino	Prostate cancer	CRPC	4	1.0	Stage 4	Stage 4	0.0328542094455852	2		Partial Response	10.809034907597535	0	22.57084188911704	0	Y	Y				R	PRAD	1.5405304e-08	1.0	R
102-0032	33	CD8 LOW	Nivolumab + Ipilimumab			58	F	White	Not Hispanic or Latino	Colorectal cancer	CRCA	5+	1.0	Stage 1	Stage 4	1.4127310061601643	11		Progressive Disease	2.1355236139630387	1	2.234086242299795	0	N	N		MSI-Stable	0.88	NR	COAD	1.0	2.328632e-20	NR
102-0033	34	CD8 LOW	Nivolumab + Ipilimumab			72	F	White	Not Hispanic or Latino	Hepatocellular carcinoma	HCCA	5+	1.0	Stage 4	Stage 4	0.7227926078028748	1	0.0	Progressive Disease	2.299794661190965	1	11.203285420944558	1	N	N	N	MSI-Stable	1.75	NR	LIHC	1.0	3.037579e-08	NR
102-0038	37	CD8 LOW	Nivolumab + Ipilimumab			64	M	White	Not Hispanic or Latino	Head and neck cancer	HNCA	5+	1.0	Stage 4	Stage 4	1.4127310061601643	1	5.0	Stable Disease	2.004106776180698	0	2.3983572895277208	0	N	N	N	MSI-L	3.06	NR	HNSC	0.9997918	0.00020821833	NR
102-0041	74	CD8 HIGH	Nivolumab	Y	53.0	39	M	White	Not Hispanic or Latino	Head and neck cancer	HNCA	5+	1.0	Stage 4	Stage 4	2.529774127310062	36		Progressive Disease	1.5112936344969197	1	3.1868583162217656	0	N	N		MSI-Stable	1.43	NR	HNSC	0.99996376	3.6241607e-05	NR
102-0044	75	CD8 HIGH	Nivolumab			55	M	Other	Not Hispanic or Latino	Head and neck cancer	HNCA	4	1.0	Stage 4	Stage 4	3.7782340862423	16	33.0	Stable Disease	3.7125256673511298	0	3.7782340862423	0	N	N		MSI-Stable	4.88	NR	HNSC	0.9999995	4.9990314e-07	NR
102-0048	42	CD8 LOW	Nivolumab + Ipilimumab			60	M	White	Not Hispanic or Latino	Pelvic neoplasm	PELV	5+	1.0	Stage 1	Stage 4	0.0328542094455852	4			0.0328542094455852	0	0.2628336755646817	0	N	N		MSI-Stable	0.89		SARC	0.004406518	0.9955935	R
103-0001	43	CD8 LOW	Nivolumab + Ipilimumab			32	M	Other	Not Hispanic or Latino	Sarcoma	SARC	5+	0.0		Stage 4	1.6098562628336754	1	1.0	Progressive Disease	0.164271047227926	1	8.870636550308008	1	N	N	N	MSI-Stable	0.62	NR	SARC	1.0	5.4964648e-08	NR
103-0003	76	CD8 HIGH	Nivolumab			70	M	White	Not Hispanic or Latino	Gastrooesophageal cancer	GEJC	1	0.0	Stage 1	Stage 4	26.217659137577	22	42.0	Partial Response	9.19917864476386	1	30.12731006160164	0	Y	Y		MSI-Stable	2.83	R	STAD	0.004968368	0.9950316	R
104-0001	44	CD8 LOW	Nivolumab + Ipilimumab			77	M	White	Not Hispanic or Latino	Prostate cancer	CRPC	5+	1.0	Stage 4	Stage 4	1.215605749486653	8			1.5770020533880904	1	1.5770020533880904	1	N	N		MSI-Stable	0.85		PRAD	1.0	1.7163844e-08	NR
104-0014	51	CD8 LOW	Nivolumab + Ipilimumab			64	F	White	Hispanic or Latino	Tumour of ampulla of Vater	AMPV	0	0.0	Stage 2	Stage 4	1.4127310061601643	6		Progressive Disease	1.938398357289528	1	6.406570841889117	1	N	N				NR	COAD	0.9997694	0.00023065624	NR
104-0015	52	CD8 LOW	Nivolumab + Ipilimumab			58	F	White	Not Hispanic or Latino	Thyroid cancer	THYR	4	0.0	Stage 4	Stage 4	5.092402464065708	1	9.0	Stable Disease	5.092402464065708	1	6.669404517453799	0	N	N	N	MSI-Stable	0.33	NR	THCA	0.62676334	0.37323666	NR
104-0016	53	CD8 LOW	Nivolumab + Ipilimumab			74	F	Other	Not Hispanic or Latino	Uterine cancer	UTCA	4	1.0	Stage 3	Stage 4	0.0328542094455852	2			0.919917864476386	1	0.919917864476386	1	N	N		MSI-L	2.13		UCEC	1.0	3.345828e-11	NR
104-0020	55	CD8 LOW	Nivolumab + Ipilimumab			80	M	White	Not Hispanic or Latino	Prostate cancer	CRPC	5+	0.0	Stage 2	Stage 4	17.51129363449692	1	1.0	Stable Disease	14.061601642710473	1	27.92607802874744	1	N	Y	N	MSI-Stable	0.7	NR	PRAD	0.00090475235	0.9990953	R
104-0021	56	CD8 LOW	Nivolumab + Ipilimumab			68	M	White	Not Hispanic or Latino	Prostate cancer	CRPC	2	0.0	Stage 4	Stage 4	3.02258726899384	4	16.0	Partial Response	7.523613963039015	0	26.907597535934293	0	Y	Y	Y	MSI-Stable	0.84	R	PRAD	0.9999989	1.1220847e-06	NR
104-0022	57	CD8 LOW	Nivolumab + Ipilimumab			63	F	Asian	Not Hispanic or Latino	Ovarian cancer	OVCA	3	1.0	Stage 1	Stage 4	1.4127310061601643	7	3.0	Progressive Disease	1.8726899383983573	1	25.626283367556468	0	N	N	N			NR	OV	0.9999949	5.107378e-06	NR
104-0023	58	CD8 LOW	Nivolumab + Ipilimumab			63	F	White	Not Hispanic or Latino	Colorectal cancer	CRCA	2	1.0	Stage 4	Stage 4	0.7227926078028748	0	0.0		4.205338809034908	1	4.205338809034908	1	N	N	N	MSI-L	0.87		COAD	1.0	1.367669e-20	NR
106-0002	62	CD8 LOW	Nivolumab + Ipilimumab			65	M	Other	Hispanic or Latino	Head and neck cancer	HNCA	0	1.0	Stage 3	Stage 4	0.7227926078028748	1	1.0		1.5112936344969197	1	1.5112936344969197	1	N	N	N	MSI-Stable	0.79		HNSC	0.8875418	0.11245819	NR
106-0005	64	CD8 LOW	Nivolumab + Ipilimumab			42	M	White	Not Hispanic or Latino	Sarcoma	SARC	3	1.0	Stage 2	Stage 4	0.0328542094455852	0			0.6899383983572895	1	0.6899383983572895	1	N	N		MSI-L	0.46		SARC	1.0	1.0020733e-08	NR
106-0010	68	CD8 LOW	Nivolumab + Ipilimumab			77	F	White	Not Hispanic or Latino	Ovarian cancer	OVCA	2	1.0	Stage 4	Stage 4	3.9753593429158114	13	28.0	Partial Response	3.9425051334702257	1	28.057494866529773	0	Y	Y	Y	MSI-Stable	1.14	R	OV	7.3878495e-05	0.9999261	R
107-0001	70	CD8 LOW	Nivolumab + Ipilimumab			60	M	White	Not Hispanic or Latino	Neuroendocrine carcinoma of the skin	NESK	1	0.0	Stage 1	Stage 4	17.248459958932237	6		Partial Response	18.201232032854207	0	23.260780287474333	0	Y	Y		MSI-Stable	20.46	R	SKCM	0.9912067	0.008793323	NR
107-0007	79	CD8 HIGH	Nivolumab	Y	65.0	54	M	White	Not Hispanic or Latino	Head and neck cancer	HNCA	2	0.0	Stage 1	Stage 4	3.5154004106776178	23		Progressive Disease	2.0698151950718686	1	12.123203285420946	1	N	N		MSI-L	2.3	NR	HNSC	0.9929195	0.0070804735	NR
